About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Elevated Rate Pacing of Cardiac Amyloidosis | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT07583823

Elevated Rate Pacing of Cardiac Amyloidosis

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preex...

Lead sponsor: University of Minnesota•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Meghan Muscala

CONTACT

612-626-5863 payne324@umn.edu

Sponsors

Lead Sponsor

University of Minnesota

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults 18 and older
•Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
•Implanted Cardiac Pacemaker (+/- Defibrillator)
•Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
•Non-dilated left ventricle by echocardiography
•Ability to provide written consent
•English Speaking

Exclusion Criteria

•Paced QRS duration of \>150 ms (indicator for pacing mediated dyssynchrony)
•Dilated left ventricle

Related studies

Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

NCT06427304 · Cardiac Amyloidosis

Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF

NCT07250529 · Atrial Fibrillation (AF), Pacemaker Therapy, and more

Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion

NCT07342036 · Tricuspid Valve Regurgitation, Pacemaker, and more

RECRUITINGPhase 4

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

NCT07306949 · Transthyretin-type Cardiac Amyloidosis

Left Bundle Branch Area Mapping for Conduction System Pacing

NCT05884359 · Left Bundle-Branch Block, Pacemaker DDD

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 13, 2026Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment10

Start dateOct 2025

Last updatedMay 13, 2026

Condition

Cardiac Amyloidosis Pacemaker

Locations shown

University of Minnesota

Minneapolis, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 13, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions